EUCTR2008-008384-10-DE进行中（未招募）不适用
A MULTI CENTER, SINGLE-BLIND, PLACEBO-CONTROLLED PHASE 2STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRAVENOUS CD-NPIN THE TREATMENT OF PATIENTS WITH ACUTE DECOMPENSATEDHEART FAILURE (ADHF) - NIL-CDNP-CT005
ile Therapeutics, Inc.0 个研究点目标入组 75 人开始时间: 2009年3月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Be between 18 and 85 years of age, inclusive.
- •2.Systolic blood pressure = 115 mmHg and = 200 mmHg and diastolic blood pressure = 60 mmHg and = 110 mmHg at the time of screening.
- •3.Hospitalized for ADHF (decompensated chronic HF or acute HF). Patients who develop ADHF while hospitalized for another reason are not eligible.
- •4.The underlying primary etiology for ADHF should be cardiac rather than pulmonary disease. For this study, ADHF requires all of the following at the time of screening:
- •a.Dyspnea at rest (sitting or supine) or with minimal exertion (such as, talking, eating, etc.);
- •b.Pulmonary congestion on chest radiograph (X-ray) or on physical examination; and
- •c.BNP = 300 pg/mL or NT-pro-BNP = 1200 pg/mL.
- •5.Compromised renal function defined as CrCL from 30 to 89 mL/min (as estimated by either Cockcroft-Gault or Modification of Diet in Renal Disease (MDRD) Study
- •equations).
- •6.Able to begin study drug infusion within 24 hours from presentation to the hospital, including time spent in the emergency department.
- •7.Female patients must be post-menopausal or surgically sterile. A woman may be considered to be surgically sterilized if she has had a bilateral tubal ligation (for at least 6 months), bilateral oopherectomy or complete hysterectomy.
- •8.Be adequately informed of the nature and risks of the study and give written informed consent prior to receiving study medication.
- •The following criteria must continue to be met prior to study drug initiation:
- •1.Systolic blood pressure = 115 mmHg and = 200 mmHg and DBP = 60 mmHg and = 110 mmHg.
- •2.Has not received IV bolus dose of furosemide or equivalent loop diuretic including doses administered in the ambulance or emergency department, in excess of the following:
- •- 40 mg within 6 hours prior to study drug initiation
- •- 80 mg within 8 hours prior to study drug initiation
- •- 100 mg within 10 hours prior to study drug initiation
- •3. Has not received IV bolus dose of furosemide or equivalent loop diuretic within 2 hours prior to study drug initiation.
- •4.If receiving continuous IV infusion of diuretics or nitrates, the dose has not been up-titrated within 2 hours prior to dosing.
- •5.No morphine administration within 2 hours prior to dosing and able to withhold morphine administration for the first 6 hours after study drug initiation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Acute or suspected acute myocardial infarction (AMI) or troponin levels > 5X3X the upper limit of normal at the institution’s local laboratory.
- •2.Clinical diagnosis of acute coronary syndrome (ACS) within 30 days prior to screening.
- •3.Current or planned treatment with any of the following therapies prior to study drug initiation:
- •a.IV infusion of nesiritide, inotropic agents or vasopressors.
- •b. Received or planned to receive IV bolus dose(s) of furosemide or equivalent loop diuretic including doses administered in the ambulance or emergency
- •department, in excess of the following:
- •- 40 mg within 6 hours prior to study drug initiation
- •- 80 mg within 8 hours prior to study drug initiation
- •- 100 mg within 10 hours prior to study drug initiationin excess of 40 mg as a single dose
- •c.mechanical support (such as, intra-aortic balloon pumps, mechanical ventilation, or any ventricular assist device).
- •d.continuous positive positive airway pressure (CPAP).
- •e.intubation.
- •4.Cardiogenic shock.
- •5.Evidence of uncorrected volume depletion
- •6.Hyponatremia defined as serum Na = 130 mEq/L.
- •7.Clinically significant aortic or mitral valve stenosis.
- •8.Temperature > 38°C (oral or equivalent), sepsis or active infection requiring IV anti-microbial treatment.
- •9.ADHF due to significant arrhythmias (ventricular tachycardia, bradyarrhythmias with ventricular rate < 45 beats per minute or atrial fibrillation/flutter with ventricular response of > 160 beats per minute).
- •10.Severe renal failure defined as creatinine clearance < 30 mL/min as estimated by
- •both the Cockcroft-Gault estimation and the MDRD equations
- •11.Current or planned ultrafiltration, hemofiltration, or dialysis.
- •12.Significant pulmonary disease (history of oral daily steroid dependency, history of CO2 retention or need for intubation for acute exacerbation, or currently receiving IV steroids).
- •13.Any organ transplant recipient, currently listed (anticipated in the next 60 days) for transplant, or admitted for cardiac transplantation.
- •14.Major surgery within 30 days.
- •15.Major neurologic event, including cerebrovascular events in the prior 60 days.
- •16.Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns).
- •17.Known hepatic impairment as indicated by any of the following:(total bilirubin > 3 mg/dL, albumin < 2.8 mg/dL, with other signs or symptoms of hepatic dysfunction or increased ammonia levels, if performed with other signs or symptoms of hepatic dysfunction ).
- •18.Received an investigational drug within 30 days prior to screening.
- •19.Women who are pregnant or breastfeeding.
- •20.Known hypersensitivity or allergy to natriuretic peptide or its components, nesiritide, other natriuretic peptides or related compounds.
- •21.Any condition which could interfere with, or for which the treatment might interfere with the conduct of the study, or which would unacceptably increase the risk of the patient's participation in the study. This may include, but is not limited to alcoholism, drug dependency or abuse, psychiatric disease, epilepsy, or any unexplained blackouts.
- •22.Patients diagnosed with Chagas’ cardiomyopathy.
- •23. Administration of IV contrast agent within the past 48 hours
- •24. Known predisposition to excessive vasodilatation in response to blood pressure lowering medications.
研究者
相似试验
已完成
不适用
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF ACT-293987 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSIOPER-064-10Actelion Pharmaceuticals Ltd,15
已完成
不适用
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED,PARALLEL-GROUP PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OFMASITINIB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE-G30G30PER-037-16AB Science,1
进行中（未招募）
1 期
Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptomsParkinson's diseaseMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-021394-37-BECB Pharma SA345
进行中（未招募）
1 期
Placebo-controlled study in patients with Parkinson’s disease to evaluate the effect of rotigotine on nonmotor symptomsMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2010-021394-37-SKCB Pharma SA345
进行中（未招募）
不适用
Placebo-controlled study in patients with Parkinson's disease to evaluate the effect of rotigotine on nonmotor symptomsMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2010-021394-37-DECB Pharma SA345